About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2026№8

Therapy for genital mycoplasma infection: results of a prospective study

DOI
https://dx.doi.org/10.18565/aig.2026.241

Rakhmatulina M.R.

State Research Center of Dermatovenereology and Cosmetology, Ministry of Health of Russia, Moscow, Russia

Rationale. In recent years, diseases caused by genital mycoplasmas have become a leading reason for urogenital pathology. However, antimicrobial resistance among these microorganisms is increasing, necessitating the use of drugs with proven efficiency.
Objective. To evaluate the clinical and laboratory efficiency of Vilpramycin SAR (josamycin) 1000 mg in the treatment of genital mycoplasma infection.
Materials and methods. 26 patients with genital mycoplasma infection caused by M. genitalium (n=8), M. hominis (n=8), and Ureaplasma spp. (n=10) were enrolled in the study. Research methods: microscopic, molecular-biological. Vilpramycin SAR was prescribed at a dose of 1000 mg twice a day for 10 days. 
Results. Four weeks after the end of treatment, the absence of subjective and/or objective manifestations of the infectious and inflammatory processes caused by genital mycoplasmas were identified in 7/8 (87.5%; p=0.0327) patients of the 1st group, 7/8 (87.5%; p=0.0327) patients of the 2nd group and 9/10 (90.0%; p=0.0020) patients of the 3rd group. Eradication of M. genitalium was achieved in 100% of patients (p=0.0078), with eradication of M. hominis and Ureaplasma spp. in 77.8% (p=0.0020) of patients given a statistically significant decrease in the inflammatory response indices (95% CI for the difference in proportions 47.3–99.7; p=0.0327). Genital normocenosis was achieved in 8/8 (100%; p=0.0078) patients of the 1st group, 6/8 (75.0%; p=0.0327) patients of the 2nd group and 8/10 (80%; p=0.0020) patients of the 3rd group.
Conclusion. Vilpramycin SAR (josamycin) at a dose of 1000 mg 2 times a day for 10 days demonstrates high efficiency in the treatment of genital mycoplasma infection, and can be characterized by safety and tolerability, ensuring treatment compliance. 

Conflict of interest. The author declares no conflict of interest.
Funding. The sponsor of the study was PROMOMED DM LLC (Russia). 
Ethical Approval. The study was approved by the local ethics committee of the State Scientific Center for Dermatovenerology and Cosmetology, Ministry of Health of Russia.
Generative Artificial Intelligence. No generative AI technologies were used in this article.
Patient Consent for Publication. All patients signed informed consent for the publication of their data.
Authors' Data Sharing Statement. The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Rakhmatulina M.R. Therapy for genital mycoplasma infection: 
results of a prospective study.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (8): 164-172 (in Russian)
https://dx.doi.org/10.18565/aig.2026.241

Keywords

genital mycoplasmas
M. genitalium
Ureaplasma
M. hominis
josamycin
Vilpramycin SAR
Full text (in Russian)

References

  1. Taylor-Robinson D. Mollicutes in vaginal microbiology: mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum and Mycoplasma genitalium. Res. Microbiol. 2017; 168(9-10): 875-81. https://dx.doi.org/10.1016/j.resmic.2017.02.009
  2. Taylor-Robinson D. Thoughts about Mycoplasma hominis. Sex. Transm. Infect. 2020; 96(7): 492. https://dx.doi.org/10.1136/sextrans-2020-054479
  3. Рахматулина М.Р., Шашкова А.А. Клиническое значение выявления генитальных микоплазм и современные показатели чувствительности Ureaplasma и M. hominis к антибактериальным препаратам. Акушерство и гинекология. 2016; 12: 137-42. https://dx.doi.org/10.18565/aig.2016.12.137-42 [Rakhmatulina M.R., Shashkova A.A. The clinical significance of detecting genital mycoplasmas and the current indicators of antibiotic susceptibility of Ureaplasma and M. hominis. Obstetrics and Gynecology. 2016; (12): 137-42 (in Russian). https://dx.doi.org/10.18565/aig.2016.12.137-42].
  4. Centers for Disease Control and Prevention (CDC). Clinical overview of HPV. Available at: https://www.cdc.gov/hpv/hcp/clinical-overview/index.html (accessed February 6, 2025).
  5. Jensen J.S., Cusini M., Gomberg M., Moi H., Wilson J., Unemo M. 2021 European guideline on the management of Mycoplasma genitalium infections. J. Eur. Acad. Dermatol. Venereol. 2022; 36(5): 641-50. http://dx.doi.org/10.1111/jdv.17972
  6. Horner P., Donders G., Cusini M., Gomberg M., Jensen J.S., Unemo M. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? - a position statement from the European STI Guidelines Editorial Board. J. Eur. Acad. Dermatol. Venereol. 2018; 32(11): 1845-51. http://dx.doi.org/10.1111/jdv.15146
  7. Рахматулина М.Р., Касаткина И.С. О роли генитальных микоплазм в развитии патологических процессов урогенитальной системы у детей. Вестник дерматологии и венерологии. 2011; 87(1): 15-22. http://dx.doi.org/10.25208/vdv922 [Rakhmatulina M.R., Kasatkina I.S. The role of Genital Mycoplasmas for the development of urogenital pathology in children. Vestn. Dermatol. Venerol. 2011; 87(1): 15-22 (in Russian). https://dx.doi.org/10.25208/vdv922].
  8. Stavart L., Baud D., Eyer M. Ureaplasma urealyticum, Ureaplasma parvum et Mycoplasma hominis: commensaux ou pathogènes? [Ureaplasma urealyticum, Ureaplasma parvum, and Mycoplasma hominis: commensals or pathogens?]. Rev. Med. Suisse. 2023; 19(845): 1835-9. French. https://dx.doi.org/10.53738/REVMED.2023.19.845.1835
  9. Jonduo M.E., Vallely L.M., Wand H., Sweeney E.L., Egli-Gany D., Kaldor J. et al. Adverse pregnancy and birth outcomes associated with Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum: a systematic review and meta-analysis. BMJ open. 2022; 12(8): e062990. https://dx.doi.org/10.1136/bmjopen-2022-062990
  10. Урогенитальные заболевания, вызванные Mycoplasma genitalium. Клинические рекомендации. Акушерство и гинекология. 2025; 9(Приложение). https://dx.doi.org/10.18565/aig.2025.266 [Urogenital diseases caused by Mycoplasma genitalium. Clinical guidelines. Obstetrics and Gynecology. 2025; 9(Supl.) (in Russian). https://dx.doi.org/10.18565/aig.2025.266].
  11. Braam J.F., van Dommelen L., Henquet C.J.M., van de Bovenkamp J.H.B., Kusters J.G. Multidrug-resistant Mycoplasma genitalium infections in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 2017; 36(9): 1565-7. https://dx.doi.org/10.1007/s10096-017-2969-9
  12. Tagg K.A., Jeoffreys N.J., Couldwell D.L., Donald J.A., Gilbert G.L. Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium. J. Clin. Microbiol. 2013; 51: 2245-9. https://dx.doi.org/10.1128/JCM.00495-13
  13. Фофанова И.Ю., Прилепская В.Н. Возможности терапии урогенитальной микоплазменной инфекции при беременности. Трудный пациент. 2009; 7(12): 17-23. [Fofanova I.Yu., Prilepskaya V.N. Possibilities of therapy of urogenital mycoplasma infection during pregnancy. Difficult patient. 2009; 7(12): 17-23 (in Russian)].
  14. Guschin A., Ryzhikh P., Rumyantseva T., Gomberg M., Unemo M. Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin. BMC Infect. Dis. 2015; 15: 40. https://dx.doi.org/10.1186/s12879-015-0781-7
  15. Beeton M.L., Spiller O.B. Antibiotic resistance among Ureaplasma spp. isolates: cause for concern? J. Antimicrob. Chemother. 2017; 72(2): 330-7. https://dx.doi.org/10.1093/jac/dkw425
  16. Osono T. Efficacy rates and side effects in Josamycin treatment. Post-marketing surveillance of 27090 cases covering 1971-1978. Basis information Josalid; 1979.
  17. Скрябина А.А., Никифоров В.В., Шахмарданов М.З., Застрожин М.С., Скрябин В.Ю., Сычев Д.А. Нежелательные реакции, возникающие на фоне терапии макролидами: анализ спонтанных сообщений по данным подсистемы «Фармаконадзор». Клиническая микробиология и антимик­робная химиотерапия. 2023; 25(1): 34-40. https://dx.doi.org/10.36488/cmac.2023.1.34-40 [Skryabina A.A., Nikiforov V.V., Shakhmardanov M.Z., Zastrozhin M.S., Skryabin V.Yu., Sychev D.A. Adverse drug reactions of macrolide therapy: analysis of spontaneous reports according to the Pharmacovigilance system. Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1): 34-40 (in Russian). https://dx.doi.org/10.36488/cmac.2023.1.34-40].
  18. Zheng L.Q., Wang Q.Y. Prevalence and antimicrobial susceptibility of ureaplasma urealyticum and Mycoplasma hominis in female outpatients, 2017-2021. Clin. Lab. 2023; 69(5). https://dx.doi.org/10.7754/Clin.Lab.2022.220912
  19. Zheng J., Li Y., Zhao J., Yan J. Study on drug resistance to treatment for ureaplasma Urealyticum infections in the female genital tract. Clin. Lab. 2024; 70(4). https://dx.doi.org/10.7754/Clin.Lab.2024.231146
  20. Moridi K., Hemmaty M., Azimian A., Fallah M.H., Khaneghahi Abyaneh H., Ghazvini K. Epidemiology of genital infections caused by Mycoplasma hominis, M. genitalium and Ureaplasma urealyticum in Iran; a systematic review and meta-analysis study (2000-2019). BMC Public Health. 2020; 20(1): 1020. https://dx.doi.org/10.1186/s12889-020-08962-5
  21. Эйдельштейн И.А., Гущин А.Е., Гладин Д.П., Романов А.В., Негашева Е.С., Фриго Н.В., Козлов Р.С., Потекаев Н.Н., Козлова Н.С., Борухович Д.Г. Высокая распространенность резистентности к макролидам и фторхинолонам у Mycoplasma genitalium, выделенных у пациентов из двух мегаполисов России – Москвы и Санкт-Петербурга в 2021-2024 гг. Клиническая микробиология и антимикробная химиотерапия. 2024; 26(3): 356-69. https://dx.doi.org/10.36488/cmac.2024.3.356-369 [Eidelstein I.A., Gushchin A.E., Gladin D.P., Romanov A.V., Negasheva E.S., Frigo N.V., Kozlov R.S., Potekaev N.N., Kozlova N.S., Borukhovich D.G. High prevalence of resistance to macrolides and fluoroquinolones in Mycoplasma genitalium isolated from patients from two Russian megacities – Moscow and St. Petersburg in 2021-2024. Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(3): 356-69 (in Russian). https://dx.doi.org/10.36488/cmac.2024.3.356-369].
  22. Aujard Y., Maury L., Doit C., Mariani-Kurkdjian P., Baud O., Farnoux C., Bingen E. Ureaplasma urealyticum and Mycoplasma hominis infections in newborns: personal data and review of the literature. Arch. Pediatr. 2005; 12(Supl.1): 12-8. https://dx.doi.org/10.1016/s0929-693x(05)80004-1
  23. Changzheng H., Zhixiang L., Nengxing L., Yating T., Jiawen L., Demei Z. Susceptibility of mixed infec infection of Ureaplasma Urealyticum and Mycoplasma hominis to seven antimicrobial agents and comparison with that of Ureaplasma urealyticum infection. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2003; 23(2): 203-5. https://dx.doi.org/10.1007/BF02859959
  24. Шапран М.В. Чувствительность Ureaplasma urealyticum к антибиотикам. Consilium Medicum. 2005; 7(1): 37-8. [Shapran M.V. Sensitivity of Ureaplasma urealyticum to antibiotics. Consilium Medicum. 2005; 7(1): 37-8 (in Russian)].
  25. Гамова Н.А. Чувствительность к лекарственным препаратам Ureaplasma urealyticum, персистирующих в организме больных при хронических воспалительных заболеваниях урогенитального тракта. Журнал микробиологии. 2003; 4: 81-5. [Gamova N.A. Sensitivity to Ureaplasma urealyticum drugs that persist in patients with chronic inflammatory diseases of the urogenital tract. Journal of Microbiology. 2003; 4: 81-85 (in Russian)].
  26. Открытое рандомизированное перекрестное репликативное четырех­периодное исследование сравнительной фармакокинетики и биоэквивалентности препарата ATBC10901 (ООО «ПРОМОМЕД РУС», Россия) с участием здоровых добровольцев. Протокол исследования: №JOS-022023. [Open randomized, cross-replicative, four-period study of comparative pharmacokinetics and bioequivalence of ATBC10901 (PROMOMED RUS LLC, Russia) with healthy volunteers. Study Protocol: No. JOS-022023 (in Russian)].
  27. Аполихина И.А., Горбунова Е.А., Додова Е.Г., Гасанова Г.Ф. Современные аспекты комбинированной антибактериальной терапии неспецифических вагинитов и цервицитов в (результаты неинтервенционного исследования «Баланс»). Акушерство и гинекология. 2015; 8: 70-7. [Apolikhina I.A., Gorbunova E.A., Dodova E.G., Gasanova G.F. Current aspects of combination antibiotic therapy for nonspecific vaginitis and cervicitis: Results of the non-interventional study Balance. Obstetrics and Gynecology. 2015; (8):70-7 (in Russian)].
  28. Minguez F., Ramos C., Loscos A., Chiu M.L., Prieto J. In vitro killing kinetics and postantibiotic effect of josamycin and other macrolides on several bacteria. Chemotherapy. 1993; 39(3): 163-8. https://dx.doi.org/10.1159/000239121

Received 06.08.2026

Accepted 21.08.2026

About the Authors

Margarita R. Rakhmatulina, Dr. Med. Sci., Professor, Deputy Director for Organizational and Analytical Work, State Research Center of Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation, 3 Korolenko str., Building 6, Moscow, 107076, Russia, +7(499)785-20-48, ra.marg@yandex.ru,
https://orcid.org/0000-0003-3039-7769

Similar Articles

№10 / 2023
Shipitsyna E.V., Pachulia O.V., Bespalova O.N., Kogan I.Yu.
The role of ureaplasmas in the development of preterm birth: renewed discussion in light of new data
№11 / 2018
Gadzhieva Z.K., Gomberg M.A., Grigoryan V.A., Gazimiev M.A., Kazilov Yu.B.
Specific features of diagnosis and treatment in pregnant women with uncomplicated urinary tract infection and urogenital infections
№12 / 2016
Rakhmatulina M.R., Shashkova A.A.
The clinical significance of detecting genital mycoplasmas and the current indicators of antibiotic susceptibility of Ureaplasma and M. hominis
№8 / 2015
Apolikhina I.A., Gorbunova E.A., Dodova E.G., Gasanova G.F.
Current aspects of combination antibiotic therapy for nonspecific vaginitis and cervicitis: Results of the non-interventional study Balance
№9 / 2025
Apolikhina I.A., Tarnaeva L.A.
The role of josamycin in the treatment of the lower genital tract inflammation in women
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.